Serum sclerostin and adverse outcomes in elderly patients with stable coronary artery disease undergoing percutaneous coronary intervention

Wuyang He1 · Chunqiu Li1 · Qingwei Chen1 · Tingting Xiang1 · Peng Wang1 · Jun Pang1

Received: 29 July 2019 / Accepted: 17 October 2019 / Published online: 1 November 2019 © The Author(s) 2019

Abstract

Background Recently, sclerostin, a bone-derived protein, has been shown to play a key role in atherosclerosis progression. However, few studies have investigated the influence of sclerostin on cardiovascular disease prognosis. We investigated the relationship between serum sclerostin levels and adverse outcomes in elderly patients with stable coronary artery disease (SCAD) who were undergoing percutaneous coronary intervention (PCI).

Methods We enrolled 310 elderly SCAD patients who underwent PCI in this study and followed them 3 years. According to the median serum sclerostin levels, subjects were stratified into a low sclerostin (low scl) group (n = 144) and a high sclerostin (high scl) group (n = 166). Time-to-event analyses were performed with the Kaplan–Meier method. Associations between sclerostin levels and main adverse cardiovascular and cerebrovascular events (MACCEs) and mortality were evaluated by Cox multivariate regression analysis. The prognostic power of predictive models was verified by the concordance index and receiver operating characteristic curve analysis.

Results The high scl group had a significantly higher MACCE-free rate and better survival than the low scl group. Serum sclerostin was an independent predictor and could improve the prognostic power for adverse outcomes. In addition, serum sclerostin levels were significantly associated with bone turnover markers, a lower presence of multivessel disease and a lower CCS angina class.

Conclusions Serum sclerostin is a prognostic parameter for predicting and intervening in the adverse outcomes of elderly SCAD patients undergoing PCI, which may be explained by its potential role in the bone–vascular axis.

Keywords Sclerostin · Stable coronary artery disease · Percutaneous coronary intervention · Elderly

Introduction

Coronary heart disease (CHD) has become the leading cause of death worldwide, increasing both mortality and the risk of disability in the elderly population. Several studies have reported that bone loss may increase the risk of CHD [1, 2], and its underlying mechanism could be explained by the “bone–vascular calcification paradox”. This phenomenon has been defined as the coincidence of bone loss and vascular calcification [3], revealing the common pathophysiological process between atherosclerosis and osteoporosis.

The canonical Wnt-signaling pathway promotes bone formation by stimulating the differentiation of mesenchymal stem cells (MSCs) to osteoblasts and attenuating the differentiation of osteoclasts [4, 5]. Since osteogenic differentiation of MSCs and pericytes also occurs in the process of vascular calcification [6], the canonical Wnt-signaling pathway may be involved in the link between atherosclerosis and bone loss. Sclerostin, an antagonist in the canonical Wnt-signaling pathway, can inhibit ectopic calcification in the vasculature, exerting its potential protective role by attenuating the progression of atherosclerosis [7]. The role

Electronic supplementary material The online version of this article (https://doi.org/10.1007/s40520-019-01393-2) contains supplementary material, which is available to authorized users.

Qingwei Chen
chenqwcq@sohu.com; chenqwcq@163.com

1 Department of Geriatric Cardiology, The Second Affiliated Hospital of Chongqing Medical University, No 76 Linjiang Road, Chongqing 400010, China

Wuyang He, Chunqiu Li made equal contributions to the work.
of sclerostin can also be supported by the overexpression of sclerostin in calcified aortic vascular tissue [8]. Thus, investigating the influence of circulating sclerostin on the prognosis of CHD could provide a new target for improving survival and lifespan in elderly populations.

Recent data have demonstrated that circulating sclerostin levels are positively correlated with better survival in patients undergoing hemodialysis [9]. Nevertheless, other studies have shown that higher serum sclerostin levels increase all-cause mortality in patients with chronic kidney disease (CKD) [10]. Despite these contradictory findings, few studies have investigated the relationship in patients with normal renal function. Therefore, we followed a cohort of elderly stable coronary artery disease (SCAD) patients without CKD to assess the relationships between serum sclerostin levels and adverse outcomes after percutaneous coronary intervention (PCI).

Materials and methods

Participants and study design

A total of 310 elderly SCAD patients who underwent PCI at the Department of Geriatric Cardiology of the Second Affiliated Hospital of Chongqing Medical University (CQMU) between Jan 2014 and Dec 2015 were enrolled in this study. Participants were stratified into 2 groups according to the median value of serum sclerostin levels: those with low serum sclerostin levels (the low scl group) and those with high sclerostin levels (the high scl group). All subjects satisfied the following inclusion criteria: age ≥ 65 years, a diagnosis of SCAD [11], eligibility for PCI met, and willingness to participate in the study and sign a written informed consent form. The exclusion criteria included (1) a recent presence of acute coronary syndrome within 3 months; (2) PCI within 3 months or had a previous or planned CABG; (3) left main coronary artery disease, left ventricular ejection fraction < 50% as assessed by echocardiography, or Canadian Cardiovascular Society (CCS) angina class IV; (4) an eGFR < 45 mL/min/1.73 m²; (5) a diagnosis of infectious or autoimmune disease or current use of an anti-inflammatory treatment; (6) a history of hepatic insufficiency, significant valvular disease, CKD, a thyroid disorder or a malignant tumor; or (7) current treatment with drugs that could affect bone metabolism and serum sclerostin levels, such as calcium, vitamin D, thyroid hormone, thiazolidinedione, warfarin, or aspirin.

Our study was performed with the approval of the ethics committee of the Second Affiliated Hospital of CQMU, and informed consent was obtained from all participants.

Clinical analysis

At baseline, age, sex, alcohol consumption, smoking habit, history of diseases, and medication usage history were collected through a specific questionnaire. Height and weight were measured by standardized methods. BMI was calculated using the weight divided by the square of the height. Blood pressure was measured using a standard mercury sphygmomanometer (12 cm long and 35 cm wide) after letting the subject rest for more than 5 min. The blood pressure for each subject was measured twice, and the mean value was recorded. The bone mineral density (BMD) of all subjects was measured at the lumbar spine (LS) and femoral neck (FN) by dual energy X-ray absorptiometry (GE Lunar iDxA, America).

Frailty status was assessed using the frailty phenotype (FP) scale [12]. The presence of more than three items on the scale was defined as frailty.

The physical activity of all subjects was measured by the Chinese version of the International Physical Activity Questionnaire (IPAQ) short form, which has been validated to be accurate in the Chinese population [13]. Based on intensity, physical activity was classified as vigorous activity (VA), moderate activity, or walking and was evaluated by the frequency and duration of physical activity in the previous 7 days [14].

Baseline biomedical measurements

Overnight venous blood samples were collected on the morning of PCI. Biochemical parameters included traditional cardiovascular risk factors [such as levels of triglyceride (TG), total cholesterol (TC), LDL-cholesterol (LDL-c), HDL-cholesterol (HDL-c), hypersensitive C-reactive protein (hs-CRP), glycated hemoglobin (HbA1c), creatine, etc.] and bone turnover markers [such as levels of parathyroid hormone (PTH), 25-hydroxyvitamin D (25(OH)D), bone alkaline phosphatase (BALP), N-terminal propeptide of type I procollagen (PINP), N-terminal midfragment of osteocalcin (N-MID osteocalcin), and C-terminal cross-linking telopeptide of type I collagen (β-CTX)] were immediately measured by standard biochemical methods. Moreover, all serum samples were stored at – 80 °C for the measurement of sclerostin. According to the manufacturer’s instructions, serum levels of sclerostin were measured by ELISA (DY1406, R&D SYSTEMS, America). The limit of detection was 41.5 pg/mL. The intra- and interassay variability were both lower than 10%.

CAD severity

Coronary angiography was performed using the Judkins technique via the radial artery. CAD severity was then evaluated using the SYNTAX score by two experienced interventional cardiologists who were not aware of the clinical
results of the patients. SYNTAX score calculator 2.1 (www.syntaxscore.com) was used to measure the SYNTAX score for all coronary lesions, which was $> 50\%$ diameter stenosis in a vessel $> 1.5$ mm.

**Follow-up and outcome analysis**

Follow-up with all subjects was achieved via telephone interview or was based on medical records obtained from the Second Affiliated Hospital of CQMU at 1 month, 6 months, 1 year, 2 years, and 3 years after PCI. The presence of main adverse cardiovascular and cerebrovascular events (MACCEs) (including all-cause death, stroke, myocardial infarction (MI) and repeat revascularization) was regarded as the primary endpoint. The prespecified secondary endpoints were the individual MACCE components and cardiovascular mortality.

**Definitions**

Hypertension was defined based on a systolic blood pressure $\geq 140$ mmHg, a diastolic blood pressure $\geq 90$ mmHg or the use of antihypertension medication [15]. Type 2 diabetes mellitus (T2DM) was defined based on a level of HbA1c $\geq 6.5\%$ or on a fasting glucose level $\geq 126$ mg/dL obtained on two separate days or on the use of antidiabetic medication. Osteoporotic (OP) patients were diagnosed with prior fragility fractures or densitometry, defined by a T-score of $-2.5$ or less. Peripheral artery disease was diagnosed according to the ACC/AHA guidelines [16]. Myocardial infarction and stroke were defined based on ischemic symptoms and clinical guidelines [17, 18].

**Statistical analysis**

The Kolmogorov–Smirnov test was used to test the normality of continuous variables. Normally distributed variables between two groups were compared by Student’s $t$ test. The Mann–Whitney $U$ test was used to compare skewed variables. The data are shown as counts with percentages for qualitative values and as the means $\pm$ standard deviations (SDs) or medians with interquartile ranges for quantitative values. The $\chi^2$ test was used to compare categorical variables, which are presented as percentages. The linear regression analysis was used to assess the association between serum sclerostin and other clinical parameters. The Kaplan–Meier method was used to perform time-to-event analyses, which were compared between patients in the low scl group and the high scl group. Multivariate Cox regression analysis was used to evaluate the relationships between the baseline characteristics and adverse outcomes. The discrimination and predictive ability of the predictive model with or without sclerostin was tested using the concordance index (C-index) and receiver operating characteristic (ROC) curve analysis. IBM SPSS Statistics version 25.0, R version 3.6.1 for Windows, and GraphPad Prism 6 were used to analyze the data, and $p$ values $< 0.05$ were considered significant.

**Results**

**Baseline characteristics**

All subjects were stratified into two groups according to the median value of serum sclerostin levels (179.5 pg/mL). The baseline characteristics are shown in Table 1. Compared with the low scl group, the high scl group had a lower prevalence of osteoporosis (42.6% vs 73.6%, $p < 0.001$), a higher BMD of the FN (0.9 vs 0.8 g/cm$^3$, median, $p < 0.001$), a higher BMD of the LS (1.0 vs 0.9 g/cm$^3$, median, $p = 0.001$), a lower rate of statin use (1.2% vs 6.3%, $p = 0.017$), and lower CCS class ratings (1.0 vs 1.0, median, $p < 0.001$). Regarding the CAD severity and angiographic characteristics, the differences between the two groups did not reach significance ($p > 0.05$).

**The association of sclerostin with adverse outcomes after PCI**

During the 3-year follow-up period, one patient was lost during follow-up, 62 patients developed at least one MACCE, and 32 patients died, of whom 14 patients’ deaths were attributed to cardiovascular mortality. The time-to-event analyses were performed via the Kaplan–Meier method. The comparison between the low scl group and the high scl group was conducted using the log-rank test. The high scl group had a significantly lower presence of MACCEs (Fig. 1), a lower risk of MI, repeat revascularization, and stroke (Online Figs. 4, 5, 6) and better survival of all-cause mortality (Fig. 2) than the low scl group (all $p < 0.05$). There was no difference in cardiovascular mortality (Fig. 3) between the two groups.

In the multivariate Cox regression analysis (Table 2, Models 1–3), serum sclerostin was an independent predictor for MACCEs (HR = 0.456, 95% CI 0.245–0.848, $p = 0.013$). Among the components of MACCEs, serum sclerostin was independently associated with the components MI (HR = 0.369, 95% CI 0.156–0.871, $p = 0.023$) and all-cause mortality (HR = 0.297, 95% CI 0.117–0.752, $p = 0.010$) rather than stroke and repeat revascularization after adjusting for conventional cardiovascular risk factors, CAD severity, angiographic characteristics, and medication. However, serum sclerostin was not an independent parameter associated with cardiovascular mortality.
Table 1 Baseline characteristics of the low and high sclerostin groups

| Characteristic                              | Low scl group (n = 144) | High scl group (n = 166) | p value  |
|---------------------------------------------|------------------------|--------------------------|----------|
| **Conventional cardiovascular disease risk factors** |                         |                          |          |
| Age, years                                  | 75 (67–83)             | 77 (69–83)               | 0.271    |
| Male sex, %                                 | 64 (44.4)              | 72 (43.6)                | 0.886    |
| Current smokers, %                          | 25 (17.4)              | 39 (23.5)                | 0.183    |
| Alcohol, %                                  | 20 (13.9)              | 29 (17.5)                | 0.389    |
| Hypertension, %                             | 96 (66.7)              | 101 (60.8)               | 0.288    |
| Diabetes, %                                 | 53 (36.8)              | 57 (34.3)                | 0.651    |
| Osteoporosis, %                             | 106 (73.6)             | 76 (45.8)                | < 0.001  |
| PAD, %                                      | 15 (10.4)              | 14 (8.4)                 | 0.550    |
| History of MI, %                            | 5 (3.5)                | 2 (1.2)                  | 0.705    |
| History of PCI, %                           | 23 (16.0)              | 24 (14.5)                | 0.711    |
| **Systolic BP, mmHg**                       | 130 (119.3–136.0)      | 127 (117.8–136.0)        | 0.472    |
| **Diastolic BP, mmHg**                      | 75 (68–80)             | 72 (67–80)               | 0.246    |
| **BMI (kg/m^2)**                            | 23.0 (20.8–24.9)       | 23.3 (20.8–25.5)         | 0.378    |
| **SCr (µmol/L)**                            | 71.6 (58.7–89.6)       | 72.0 (59.2–86.4)         | 0.999    |
| **HbA1c, %**                                | 61.1 (57.7–6.7)        | 6.2 (5.9–6.7)            | 0.064    |
| **TG, mmol/L**                              | 1.2 (0.8–1.9)          | 1.3 (1.0–1.8)            | 0.311    |
| **TC, mmol/L**                              | 4.5 ± 1.1              | 4.5 ± 1.0                | 0.994    |
| **LDL–C, mmol/L**                           | 2.5 ± 0.9              | 2.5 ± 0.8                | 0.886    |
| **HDL–C, mmol/L**                           | 1.2 ± 0.3              | 1.2 ± 0.3                | 0.774    |
| **CCS class**                               | 1.0 (1.0–2.0)          | 1.0 (1.0–1.0)            | < 0.001  |
| **Frailty, %**                              | 37 (25.7)              | 54 (32.5)                | 0.187    |
| **VA, %**                                   | 15 (10.4)              | 17 (10.2)                | 0.960    |
| **Bone turnover markers**                   |                         |                          |          |
| **PTH, pg/mL**                              | 32.7 (21.8–45.6)       | 32.7 (20.1–52.7)         | 0.828    |
| **CT, pg/mL**                               | 18 (1.2–2.6)           | 18 (1.2–3.1)             | 0.120    |
| **25 (OH)D, ng/mL**                         | 14.5 (9.7–22.5)        | 16.7 (10.8–28.2)         | 0.143    |
| **BALP, µg/L**                              | 10.2 (8.2–13.1)        | 9.8 (8.0–12.3)           | 0.320    |
| **PINP, µg/L**                              | 35.5 (26.4–46.0)       | 36.3 (24.7–49.8)         | 0.807    |
| **β-CTX, µg/L**                             | 0.4 (0.2–0.5)          | 0.4 (0.2–0.5)            | 0.369    |
| **N-MID osteocalcin, µg/L**                 | 16.4 (11.7–24.2)       | 15.8 (11.7–21.2)         | 0.192    |
| **BMD (FN), g/cm3**                         | 0.8 (0.6–0.9)          | 0.9 (0.7–1.0)            | < 0.001  |
| **BMD (LS), g/cm3**                         | 0.9 (0.8–1.1)          | 1.0 (0.9–1.2)            | 0.001    |
| **Angiographic characteristics**            |                         |                          |          |
| **SYNTAX scores ≥ 33, %**                   | 15 (10.4)              | 13 (7.8)                 | 0.428    |
| **Target vessels**                          |                         |                          |          |
| **LAD, %**                                  | 89 (61.8)              | 102 (61.4)               | 0.948    |
| **LCX, %**                                  | 48 (33.3)              | 58 (34.9)                | 0.766    |
| **RCA, %**                                  | 60 (41.7)              | 66 (39.8)                | 0.733    |
| **Multivessel disease, %**                  | 17 (11.8%)             | 27 (16.3)                | 0.262    |
| **PCI failure, %**                          | 4 (2.8)                | 5 (3.0)                  | 0.902    |
| **Total occlusion, %**                      | 71 (49.3)              | 85 (51.2)                | 0.739    |
| **Stent placement, %**                      | 130 (90.3)             | 152 (91.6)               | 0.693    |
| **Medication**                              |                         |                          |          |
| **Platelet inhibitor, %**                   | 116 (80.6)             | 132 (79.5)               | 0.820    |
| **Beta blocker, %**                         | 42 (29.2)              | 45 (27.1)                | 0.687    |
| **Statin, %**                               | 9 (6.3)                | 2 (1.2)                  | 0.017    |
| **RAS blocker, %**                          | 69 (47.9)              | 80 (48.2)                | 0.961    |

*PAD peripheral artery disease, MI myocardial infarction, PCI percutaneous coronary intervention, BP blood pressure, BMI body mass index, SCr serum creatine, HbA1c glycated hemoglobin, TG triglycerides, TC total cholesterol, LDL–C low-density lipoprotein cholesterol, HDL–C high-density lipoprotein cholesterol, CCS Canadian Cardiovascular Society, VA: vigorous activity, CT calcitonin, 25(OH)D 25-hydroxyvitamin D, BALP bone alkaline phosphatase, PINP propeptide of type I procollagen, β-CTX C-terminal cross-linked telopeptide, N-MID osteocalcin N-terminal midfragment of osteocalcin, BMD bone mineral density, FN femoral neck, LS lumber spine, LAD left anterior descending artery, LCX left circumflex artery, PCI percutaneous coronary intervention, BP blood pressure, MI myocardial infarction, PAD peripheral artery disease, SCr serum creatine, HbA1c glycated hemoglobin, TG triglycerides, TC total cholesterol, LDL–C low-density lipoprotein cholesterol, HDL–C high-density lipoprotein cholesterol, CCS Canadian Cardiovascular Society, VA: vigorous activity, CT calcitonin, 25(OH)D 25-hydroxyvitamin D, BALP bone alkaline phosphatase, PINP propeptide of type I procollagen, β-CTX C-terminal cross-linked telopeptide, N-MID osteocalcin N-terminal midfragment of osteocalcin, BMD bone mineral density, FN femoral neck, LS lumber spine, LAD left anterior descending artery, LCX left circumflex artery.*
As the independent factors in the multivariate Cox model were further adopted into the predictive model for adverse outcomes, we compared the discriminatory and predictive power of each predictive model with or without sclerostin. The C-index and AUC are presented in Online Table 4. Respectively, the predictive models with sclerostin had higher accuracy than the models excluding sclerostin in the prediction of MACCEs (C-index 0.867 vs 0.857), the component of all-cause mortality (C-index 0.773 vs 0.713) and MI (C-index 0.856 vs 0.824). The inclusion of sclerostin in the predictive model could improve the prognostic power for MACCEs (AUC 0.895 vs 0.888), all-cause mortality (AUC 0.778 vs 0.723) and MI (AUC 0.870 vs 0.839).

Table 2 Relationship between serum sclerostin levels and adverse outcomes in Cox multivariate regression analysis

| Outcome                  | Model 1                  | Model 2                  | Model 3                  |
|--------------------------|--------------------------|--------------------------|--------------------------|
| Outcome HR 95% CI p value| Outcome HR 95% CI p value| Outcome HR 95% CI p value| Outcome HR 95% CI p value|
| MACCEs                   | 0.461 0.252–0.844 0.012  | 0.466 0.254–0.854 0.014  | 0.456 0.245–0.848 0.013  |
| All-cause mortality      | 0.342 0.143–0.820 0.016  | 0.342 0.143–0.822 0.016  | 0.297 0.117–0.752 0.010  |
| MI                       | 0.464 0.212–1.016 0.055  | 0.472 0.215–1.036 0.061  | 0.369 0.156–0.871 0.023  |
| Stroke                   | 1.417 0.478–4.200 0.530  | 1.582 0.520–4.816 0.419  | 1.635 0.522–5.123 0.399  |
| Repeat revascularization | 0.498 0.266–0.931 0.029  | 0.499 0.266–0.935 0.030  | 0.617 0.318–1.195 0.152  |
| Cardiovascular mortality | 0.531 0.104–2.701 0.446  | 0.525 0.103–2.680 0.439  | 0.408 0.066–2.543 0.337  |

Model 1 is adjusted for the conventional cardiovascular disease risk factors, the presence of osteoporosis, BMD(FN), BMD(LS), angiographic characteristics, and the parameters with p <0.05 in the univariate analysis. Model 2 is further adjusted for the presence of total occlusion based on model 1. Model 3 is additionally adjusted for the presence of total occlusion and medication based on model 1.

MACCEs main adverse cardiac and cerebral events, MI myocardial infarction, C-index concordance index, AUC area under the curve.

As the independent factors in the multivariate Cox model were further adopted into the predictive model for adverse outcomes, we compared the discriminatory and predictive power of each predictive model with or without sclerostin. The C-index and AUC are presented in Online Table 4. Respectively, the predictive models with sclerostin had higher accuracy than the models excluding sclerostin in the prediction of MACCEs (C-index 0.867 vs 0.857), the component of all-cause mortality (C-index 0.773 vs 0.713) and MI (C-index 0.856 vs 0.824). The inclusion of sclerostin in the predictive model could improve the prognostic power for MACCEs (AUC 0.895 vs 0.888), all-cause mortality (AUC 0.778 vs 0.723) and MI (AUC 0.870 vs 0.839).
The baseline parameters associated with serum sclerostin levels

In the multivariate linear regression analysis, after adjusting for conventional cardiovascular risk factors, angiographic characteristics, and the use of medication, N-MID osteocalcin ($\beta = -0.357, p < 0.001$), $\beta$-CTX ($\beta = 0.200, p = 0.012$), PINP ($\beta = 0.207, p = 0.006$), CCS class ($\beta = -0.160, p = 0.017$), PAD ($\beta = 0.132, p = 0.042$), and multivessel disease ($\beta = -0.223, p = 0.005$) remained significantly associated with serum sclerostin levels (Table 3).

Discussion

The important role of sclerostin in the kidney–bone–vascular axis has been increasingly reported. However, whether serum sclerostin is involved in extraosseous and intraosseous mineralization in patients with normal renal function remains to be investigated, and the association of sclerostin with the adverse outcomes of PCI is scarcely discussed. Our study revealed that elderly SCAD patients with high sclerostin levels had a significantly lower incidence rate of MACCEs and better survival after PCI. More importantly, we showed an independent predictive role of serum sclerostin for the risk of MACCEs, all-cause mortality, and MI, even after adjusting for other confounding factors. The inclusion of sclerostin could add to the prognostic power in predicting adverse outcomes. In addition, higher serum sclerostin levels were associated with higher PINP levels, lower CCS classes of angina, and a lower presence of multivessel disease.

In our study, patients with high sclerostin levels had a significantly lower risk of MACCEs and longer survival, which is consistent with the association between higher circulating sclerostin levels and improved survival reported by previous studies [19, 9]. Our results disclose that sclerostin could be an intervening target to reduce the risk of MACCEs and improve the survival of elderly SCAD patients after PCI. Recent data indicate that antisclerostin monoclonal antibody (Scl-Ab) therapy promotes bone formation and inhibits resorption [20], which may otherwise increase the risk of cardiovascular events [21, 22], since downregulating circulating sclerostin may induce osteogenic differentiation of pericytes and MSCs [5]. Considering that Scl-Ab is an emerging approach to metabolic bone disease, more strategies are needed to attenuate the adverse effects of Scl-Ab in elderly SCAD patients.

The current study further showed that the serum sclerostin level was an independent predictor of MACCEs and the component MI. Moreover, serum sclerostin could also enhance the accuracy and predictive ability of the predictive model, implying the evaluation of baseline serum sclerostin levels as a reliable method to monitor adverse outcomes in elderly SCAD patients undergoing PCI. Considering the strongly indicative role of vascular calcification in cardiovascular events, serum sclerostin may add prognostic power for MACCEs and its component because of its role in regulating vascular calcification [23]. While the vasculature is the most highly mineralized structure second to the skeleton, the newly developed vascular calcification can be attributed to ectopic mineralization of the vascular wall, which is activated by the canonical Wnt-signaling pathway [24, 25]. As sclerostin protein was detected via human aortic extraction using proteomic methodology [26], elevated SOST expression during osteocytic differentiation of murine vascular smooth muscle cells and increased expression of sclerostin protein in the medial calcification of mouse aorta suggests a protective role of sclerostin in halting vascular calcification via interacting with LRP4/5/6 and inhibiting the canonical Wnt pathway [25]. This finding was further verified by two different mouse models, showing that overexpression of sclerostin could prevent aortic rupture and atherosclerosis progression in the mice, decreasing the expression of osteogenic markers such as osteoprotegerin and osteopontin in aortic tissues [27].

Considering that serum sclerostin was positively associated with bone formation marker(PINP) and negatively associated with MACCEs and surrogate markers of CAD severity (including CCS angina class and presence of multivessel disease) in our study, sclerostin may be speculated to mediate the bone–vascular axis. Since serum sclerostin is secreted mainly by mature osteocytes [28], the downregulating circulating sclerostin could parallel the bone mass loss and impaired bone metabolism of elderly people, which is also supported by the higher BMD values in high scl group in this study. Bone metabolism dysfunction attributed to aging may initiate the loss of bone mass and downregulation of serum sclerostin levels, accelerating the atherosclerosis process in elderly SCAD patients undergoing PCI. Although the causal relationship

| Variable                           | $\beta$   | $T$    | $p$ values |
|------------------------------------|----------|--------|------------|
| N-MID osteocalcin                  | -0.357   | -3.729 | < 0.001    |
| $\beta$-CTX                        | 0.200    | 2.529  | 0.012      |
| PINP                               | 0.207    | 2.777  | 0.006      |
| CCS class                          | -0.160   | -2.409 | 0.017      |
| PAD                                | 0.132    | 2.040  | 0.042      |
| Multivessel disease                | -0.223   | -2.845 | 0.005      |

$N$-MID osteocalcin $N$-terminal midfragment of osteocalcin, $\beta$-CTX C-terminal cross-linked telopeptide, PINP propeptide of type I procollagen, CCS Canadian Cardiovascular Society, PAD peripheral artery disease.
still needs further verification, sclerostin tends to affect cardiovascular outcomes by mediating the dynamic process of skeletal anabolism and atherosclerosis progression based on previous and current data. Thus, enhancing bone formation and bone mass could be beneficial for improving serum sclerostin and attenuating the adverse outcomes after PCI.

Interestingly, despite the predictive ability of sclerostin for all-cause mortality in the current study, serum sclerostin was not associated with cardiovascular mortality, which differs from the independent relationship between sclerostin and cardiovascular mortality revealed by a previous result [29]. The discrepancy of the results may be attributable to the difference in demographic characteristics, considering that patients with chronic kidney disease were enrolled in the previous study and we focused on elderly SCAD patients with normal renal function. Another mechanism could be involved in the regulation of sclerostin in all-cause mortality in addition to its protective effect on the cardiovascular system. Since systemic inflammation contributes to higher mortality in elderly patients, it is evident that overexpression of sclerostin downregulated the circulating levels of inflammatory factors in transgenic mice [27]. Clinical data also support the negative association of serum sclerostin levels with inflammation and structural damage [30]. Considering that skeletal muscle mass is a predictor of mortality of patients [31, 32], lean muscle mass was decreased in SOST-deficient mice, and a negative relationship of serum sclerostin and skeletal muscle mass was also reported in healthy subjects without diabetes [33]. Given these results, we propose that sclerostin may affect all-cause mortality in elderly SCAD patients by regulating systemic inflammation and skeletal muscle mass.

There are some limitations to this study. First, a single-centered observational study might not be able to verify the causal relationship between sclerostin and adverse outcomes and show the molecular mechanism of the bone–vascular axis. In addition, further multicentered follow-up studies are also needed to illustrate the predictive role of sclerostin for adverse outcomes in patients with normal renal function. Second, the study sample was comparatively small. However, we have several strengths. First, as far as we know, the current study is the first to investigate the relationship between serum sclerostin levels and adverse outcomes of elderly SCAD patients undergoing PCI, which provides clinical basis for the further mechanistic insights. Second, the exhaustive measurement of variables (such as conventional cardiovascular risk factors, bone turnover markers, BMD, and angiographic characteristics) associated with patient outcomes after PCI were included in this study.

Conclusions

In conclusion, we confirmed, for the first time, that higher serum sclerostin levels are associated with better 3-year outcomes after PCI in elderly SCAD patients. Moreover, serum sclerostin is an independent predictive parameter that improves the prognostic power for the risk of MAC-CEs, MI, and all-cause mortality, implying that serum sclerostin may be a new target for predicting and intervening in the adverse outcomes of elderly SCAD patients. The relationship between serum sclerostin levels and adverse outcomes can be explained by the implication of sclerostin in the bone–vascular axis. Nevertheless, the underlying molecular mechanism merits further investigation.

Acknowledgements All of the authors would like to thank American Journal Experts (AJE) for providing language help.

Author contribution WH and CL contributed equally to the conceptualization, study design, data curation, data analysis and drafting of the article. QC contributed to conceptualization, supervision, project administration and critical revision of the article. TX, PW and JP were responsible for data collection and data analysis. All authors agreed on the final content of the article.

Funding This work was financed by the National Natural Science Foundation of China (NSFC) (Grant no. 31871182), the Science and Technology Project Affiliated to the Science Department of Yuzhong District of Chongqing city (Grant no. 20170406), Scientific Research Projects of Chongqing Sports Bureau (Grant no. B201812) and the Project of Chongqing Municipal Health Planning Commission (Grant no. 2017MSXM038). These funds permitted the design of the study and data collection.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Statement of human and animal rights Our study protocol was approved by the ethics committees of the Second Affiliated Hospital of Chongqing Medical University and was conducted according to the principles of the Declaration of Helsinki.

Informed consent All of the subjects signed informed consent.

Data availability statement The data that support the findings of the study are available from the corresponding author upon reasonable request.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
References

1. Chen SJ, Lin CS, Lin CL (2015) Osteoporosis is associated with high risk for coronary heart disease: a population-based cohort study. Medicine (Baltimore) 94:e1146.

2. Liu N, Chen J, Zhang K (2016) A community-based study of the relationship between coronary artery disease and osteoporosis in Chinese postmenopausal women. Coron Artery Dis 27:59–64.

3. Persy V, D’Haese P (2009) Vascular calcification and bone disease: the calcification paradox. Trends Mol Med 15:405–416.

4. Rodda SJ, McMahon AP (2006) Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors. Development 133:3231–3244.

5. Glass DA, Bialek P, Ahn JD et al (2005) Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 8:751–764.

6. Marinou K, Christodoulides C, Antoniades C (2012) Wnt signaling in cardiovascular physiology. Trends Endocrinol Metab 23:628–636.

7. Gaudio A, Privitera F, Pulvirenti I et al (2014) The relationship between inhibitors of the Wnt signalling pathway (sclerostin and Dickkopf-1) and carotid intima-media thickness in postmenopausal women with type 2 diabetes mellitus. Diabetes Vascular Dis Res 11:48–52.

8. Brandenburg VM, Kramann R, Koos R (2013) Relationship between sclerostin and cardiovascular calcification in hemodialysis patients: a cross-sectional study. BMC Nephrol 14:219.

9. Jean G, Chazot C, Bresson E et al (2016) High serum sclerostin levels are associated with a better outcome in haemodialysis patients. Nephron 132:181–190.

10. Gonçalves FLC, Elias RM, Dos Reis LM et al (2014) Serum sclerostin is an independent predictor of mortality in hemodialysis patients. BMC Nephrol 15:190.

11. Montalescot G, Sechtem U, Achenbach S (2013) ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 34:2949–3003.

12. Fried LP, Tangen CM, Walston J et al (2001) Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 56:M146–M156.

13. Lee PH, Yu YY, McDowell I (2011) Performance of the international physical activity questionnaire (short form) in subgroups of the Hong Kong Chinese population. Int J Behav Nutr Phys Act 8:81.

14. Craig CL, Marshall AL, Sjöström M (2003) International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc 35:1381–1395.

15. Williams B, Mancia G, Spiering W et al (2018) 2018 ESC/ESH Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens 36:1953–2041.

16. Gerhard-Herman MD, Gornik HL, Barrett C et al (2017) 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 69:e71–e126.

17. Thygensen K, Alpert JS, Jaffe AS et al (2019) Fourth universal definition of myocardial infarction (2018). Eur Heart J 40:237–269.

18. Birschel P, Ellul J, Barer D (2004) Progressing stroke: towards an internationally agreed definition. Cerebrovasc Dis 17:242–252.

19. Drechsler C, Evenepoel P, Vervloet MG et al (2015) High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study. Nephrol Dial Transplant 30:288–293.

20. Drake MT, Farr JN et al (2014) Inhibitors of sclerostin: emerging concepts. Curr Opin Rheumatol 26:447–452.

21. Rosen CJ (2017) Romosozumab—promising or practice changing. N Engl J Med 377:1479–1480.

22. Javaheri B, Herbert E, Hopkinson M et al (2019) Sost haploinsufficiency provokes peracute lethal cardiac tamponade without rescuing the osteopenia in a mouse model of excess glucocorticoids. Am J Pathol 189:753–761.

23. Lee YT, Ng HY, Chiu TTY et al (2016) Association of bone-derived biomarkers with vascular calcification in chronic hemodialysis patients. Clinica Chimica Acta 452:38–43.

24. Xie C, Shen Y, Hu W et al (2016) Angiotensin II promotes an osteoblast-like phenotype in porcine aortic valve myofibroblasts. Aging Clin Exp Res 28:181–187.

25. Zhu D, Mackenzie NCW, Millan JL et al (2011) The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells. PloS One 6:e19595.

26. Didangelos A, Yin X, Mandal K et al (2010) Proteomics characterization of extracellular space components in the human aorta. Mol Cell Proteomics 9:2048–2062.

27. Krishna SM, Seto SW, Jose RJ et al (2017) Wnt signaling pathway inhibitor sclerostin inhibits angiogenesis II-induced aortic aneurysm and atherosclerosis. Arterioscler Thromb Vasc Biol 37:553–566.

28. Szulc P, Bertholon C, Borel O et al (2013) Lower fracture risk in older men with higher sclerostin concentration: a prospective analysis from the MINOS study. J Bone Miner Res 28:855–864.

29. Wang XR, Yuan L, Zhang JJ et al (2017) Serum sclerostin values are associated with abdominal aortic calcification and predict cardiovascular events in patients with chronic kidney disease stages 3–5D. Nephrology 22:286–292.

30. Gercik O, Solmaz D, Coban E et al (2019) Evaluation of serum fibroblast growth factor-23 in patients with axial spondyloarthritis and its association with sclerostin, inflammation, and spinal damage. Rheumatol Int 39:835–840.

31. Mailmoun L, Bouallègue FB, Gelis A et al (2019) Periostin and osteoblast-like phenotype in porcine aortic valve myofibroblasts. J Bone Miner Res 33:S8–S9.

32. Krause A, Speacht T, Govey P et al (2014) Sarcopenia and sarcopenia status. Bone 127:612–619.

33. Kim JA, Roh E, Hong SH et al (2019) Association of serum sclerostin levels with low skeletal muscle mass: the Korean Sarcojenic Obesity Study (KSOs). Bone 128:115053.

34. Krause A, Speacht T, Govey P et al (2014) Sarcopenia and increased body fat in sclerostin deficient mice. J Bone Miner Res 29:S8–S9.